Nanoviricides CEO Dr Anil Diwan joined Steve Darling from Proactive to discuss the company's exploration of using its antiviral candidate, NV-387, for the treatment of MPOX patients under the World Health Organization's (WHO) MEURI protocol. This comes in response to the 2024 MPOX outbreak, which is rapidly spreading across more than ten African countries, with additional cases reported in Thailand and Sweden. Dr. Diwan explained that NV-387 has already completed Phase I clinical trials for safety and tolerability, with no adverse events reported, indicating excellent safety. The compound has shown strong survival improvement in animal models, performing on par with the currently approved drug tecovirimat, demonstrating significant potential for effectiveness. As MPOX Clade 1/1b strains demand the development of new therapeutics due to limitations in existing treatments, NV-387 could play a critical role. In an animal model study simulating direct skin infection, the primary mode of MPOX transmission, NV-387 was as effective as tecovirimat, highlighting its promise as a novel broad-spectrum antiviral treatment. #proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc #NV387 #VirusTreatment #Antiviral #mPox #Biotechnology #RSV #Influenza #ClinicalTrials #HealthcareInnovation #ProactiveInvestors #PharmaceuticalResearch#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews